CureusAug 3, 2026

Effects of Glucagon-Like Peptide-1 Receptor Drugs on Reproductive Health for Obstetrician-Gynecologists

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Aug 4, 2026

Abstract

Current evidence suggests potential reproductive benefits in some patients with metabolic dysfunction or polycystic ovary syndrome (PCOS).

GLP-1 receptor agonists (RAs) and dual GIP/GLP-1 RAs are increasingly prescribed to reproductive-aged patients for obesity and type 2 diabetes.
Guidance is needed on contraception, pregnancy planning, and medication management for patients using these medications.
Pharmacokinetic interactions between GLP-1 RAs and oral hormonal contraceptives have been identified.
Safety data regarding the use of GLP-1 RAs during pregnancy and lactation remain limited.
Counseling for patients should be individualized based on pregnancy intention, contraceptive reliability, and metabolic risk.

Simplified

The expanding use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs for obesity and type 2 diabetes has important implications for reproductive-aged patients. As these medications are increasingly prescribed before conception and after delivery, obstetrician-gynecologists need practical guidance on contraception, pregnancy planning, inadvertent pregnancy exposure, medication discontinuation, gestational weight trajectory, postpartum use, and lactation. This narrative review synthesizes current evidence on GLP-1 RA and dual GIP/GLP-1 RA use across the reproductive spectrum, including mechanisms relevant to ovulation and polycystic ovary syndrome (PCOS), pharmacokinetic interactions with oral hormonal contraceptives, animal and human pregnancy safety data, preconception washout recommendations, management after inadvertent early-pregnancy exposure, postpartum prescribing, breastfeeding considerations, and unresolved research gaps. Available evidence suggests potential reproductive benefits in some patients with metabolic dysfunction or PCOS, but current pregnancy and lactation data remain limited. Until stronger prospective safety data are available, counseling should be individualized, agent-specific, and centered on pregnancy intention, contraceptive reliability, metabolic risk, and shared decision-making.

Full Text

Full text is available at the source.

View Full Text ↗

Effects of Glucagon-Like Peptide-1 Receptor Drugs on Reproductive Health for Obstetrician-Gynecologists

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief